CD34 and myelodysplastic syndrome: In addition, we have extended these findings; firstly by demonstrating aberrant CD34+CD38−CLEC12A+ cells in all MDS subtypes defined by the current 2008 WHO classification and across all IPSS‐R risk groups, hence providing evidence that this phenomenon is not restricted to high‐risk MDS or MDS with excess blasts.